IL280340B - Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection - Google Patents

Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection

Info

Publication number
IL280340B
IL280340B IL280340A IL28034021A IL280340B IL 280340 B IL280340 B IL 280340B IL 280340 A IL280340 A IL 280340A IL 28034021 A IL28034021 A IL 28034021A IL 280340 B IL280340 B IL 280340B
Authority
IL
Israel
Prior art keywords
peptides
antibodies
prevention
combinations
treatment
Prior art date
Application number
IL280340A
Other languages
Hebrew (he)
Inventor
Shulman Ziv
David Mazor Roei
Stoler-Barak Liat
ASAF Lihee
Nathan Nachum
KAGAN BEN TIKVA Sharon
Original Assignee
Yeda Res & Dev
Shulman Ziv
David Mazor Roei
Liat Stoler Barak
ASAF Lihee
Nathan Nachum
KAGAN BEN TIKVA Sharon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Shulman Ziv, David Mazor Roei, Liat Stoler Barak, ASAF Lihee, Nathan Nachum, KAGAN BEN TIKVA Sharon filed Critical Yeda Res & Dev
Priority to IL280340A priority Critical patent/IL280340B/en
Priority to PCT/IL2022/050088 priority patent/WO2022157774A1/en
Publication of IL280340B publication Critical patent/IL280340B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
IL280340A 2021-01-21 2021-01-21 Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection IL280340B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL280340A IL280340B (en) 2021-01-21 2021-01-21 Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
PCT/IL2022/050088 WO2022157774A1 (en) 2021-01-21 2022-01-20 Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL280340A IL280340B (en) 2021-01-21 2021-01-21 Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection

Publications (1)

Publication Number Publication Date
IL280340B true IL280340B (en) 2022-04-01

Family

ID=80446372

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280340A IL280340B (en) 2021-01-21 2021-01-21 Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection

Country Status (2)

Country Link
IL (1) IL280340B (en)
WO (1) WO2022157774A1 (en)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
AU737910B2 (en) 1997-01-31 2001-09-06 Regents Of The University Of California, The Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN111337672B (en) * 2020-05-18 2020-09-08 博奥赛斯（天津）生物科技有限公司 Novel enzyme-linked immunosorbent assay detection kit for coronavirus IgG antibody
CN111961138B (en) * 2020-10-20 2021-03-30 苏州茂行生物科技有限公司 Vaccine fusion proteins

Also Published As

Publication number Publication date
WO2022157774A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
EP3980400A4 (en) Peptidomimetics for the treatment of coronavirus and picornavirus infections
PH12021550542A1 (en) Multivalent pneumococcal vaccines
EP3955839A4 (en) Devices, systems and methods for the treatment of abnormal tissue
IL290792A (en) Compositions and methods for the treatment of viral infections
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
EP4061206A4 (en) Tissue treatment systems, devices, and methods
EP3745967A4 (en) Devices and methods for treating blocked blood vessels
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
SG11202103103TA (en) Gdsl lipase, genetically-engineered bacteria and application thereof
MX2021004755A (en) Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery.
ZA202211706B (en) Medicine/agent for the treatment of coronavirus, retroviral infections and hepatitis c
RS65256B1 (en) Use of nmn for the prevention and/or treatment of pain, and corresponding compositions
EP4058037A4 (en) Fibroblast-based therapy for treatment and prevention of stroke
EP4048406A4 (en) Combination therapy for the treatment of solid and hematological cancers
MX2021002909A (en) Pneumococcal fusion protein vaccines.
IL280340B (en) Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
EP3747451A4 (en) Prophylactic and/or therapeutic agent for pneumococcal infection
EP3710015A4 (en) Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
EP3833387A4 (en) Compositions and methods for preventing and treating virus infection
EP4041275A4 (en) Treatment and prevention of nephrotoxin-induced kidney injuries
IL309072A (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2010105191A3 (en) Antimicrobial compositions and methods of use therefore
EP3876967A4 (en) Therapeutic microbiota for the treatment and/or prevention of dysbiosis
MX2022015279A (en) Diagnosis, prevention and treatment of coronavirus infection.
IL308042A (en) Antibodies for the treatment and prevention of covid-19 and emerging variants